Inactive Instrument

Abpro Corporation

Equities

US0008501076

Abpro Corporation announced a financing transaction

March 30, 2017

Abpro Corporation announced that it will receive $29,999,991 in funding on March 31, 2017. The company will issue convertible preferred stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Abpro Corporation

Abpro Corporation entered into a term sheet to acquire Atlantic Coastal Acquisition Corp. II from a group of shareholders for approximately $770 million in a reverse merger transaction.	23-09-20	CI
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of Cancer Treatment Bispecific Antibody	22-09-21	CI
Abpro Corporation announced that it expects to receive $79.999992 million in funding	22-03-29	CI
Abpro Corporation Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant	21-12-09	CI
Abpro Announces Positive Phase 1 Results Demonstrating a Favorable Safety and Pharmacokinetic Profile of ABP 300, a Neutralizing Antibody Therapeutic for the Treatment of COVID-19	21-02-02	CI
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19	20-12-16	CI
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19	20-10-20	CI
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets	20-03-03	CI
Abpro Corporation announced that it expects to receive $29.999984 million in funding from Abpro Bio International, Inc.	19-10-30	CI
Abpro and NJCTTQ Enters Into Partnership for Development of Multiple Novel Bispecific Antibodies	19-02-28	CI
Abpro Corporation has withdrawn its IPO in the amount of $64 million.	18-05-16	CI
Abpro Corporation has filed an IPO in the amount of $69 million.	18-04-11	CI
Abpro Seeks Acquisitions	18-04-11	CI
Abpro Corporation announced that it has received $9.99999 million in funding	17-04-06	CI
Abpro Corporation announced a financing transaction	17-03-30	CI
Abpro Appoints MacBeath as Chief Scientific Officer	17-03-21	CI
Abpro Announces Agreements with Massachusetts General Hospital and Brigham and Women's Hospital to Co-Develop Therapeutics for Inflammation, Autoimmunity, Fibrosis, Oncology	16-05-19	CI
Abpro Announces Investment and Partnership with Essex Bio for Development of Antibody Therapeutics	16-04-06	CI
Abpro Corporation announced that it has received $3.5 million in funding from Essex Bio-Technology Limited	16-04-05	CI
Abpro Corporation announced that it has received $12.39 million in funding	16-03-23	CI
Abpro Corporation announced that it expects to receive $20 million in funding	16-03-10	CI
Abpro Corporation announced that it expects to receive $3.5 million in funding from Essex Bio-Technology Limited	16-01-21	CI

Chart Abpro Corporation

Duration

Period

More charts

Company Profile

Abpro Corporation, incorporated on August 18, 2004, is a biotechnology company that is engaged in developing antibody therapeutics. The Company is focused on antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. With the Company's Divers Immune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. The Company? s DiversImmune and MultiMab platforms and licensing strategy has generated a wide range pipeline of antibody product candidates, that includes ABP-100, ABP-110, ABP-130, ABP-300, ABP-500, ABP-201, ABP-200, and ABP-400. The Company's lead candidate, ABP-100, is a immuno-oncology TetraBi antibody that targets human epidermal growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3) for the treatment of HER2+ solid tumors, including breast, gastric, and endometrial cancers.

Sector

More about the company